Yutaka Okada

President and Representative Director, Alnylam Japan KK at Alnylam Pharmaceuticals - Cambridge, Massachusetts, US

Yutaka Okada's Colleagues at Alnylam Pharmaceuticals
Paula Cavallieri

Senior Director Regulatory Affairs - Partner & Emerging Markets

Contact Paula Cavallieri

Ilia Pharmd

Global Head of Medical Communications

Contact Ilia Pharmd

Guodong Hui

Principal CMC Biostatistician

Contact Guodong Hui

Susan Galea

Senior Director Global Patient Safety and Risk Management

Contact Susan Galea

Holly Lindgren

Principal Associate Scientist

Contact Holly Lindgren

Jose Nolasco

Director, Investigations and Operations

Contact Jose Nolasco

View All Yutaka Okada's Colleagues
Yutaka Okada's Contact Details
HQ
(617) 551-8200
Location
Tokyo,Tokyo,Japan
Company
Alnylam Pharmaceuticals
Yutaka Okada's Company Details
Alnylam Pharmaceuticals logo, Alnylam Pharmaceuticals contact details

Alnylam Pharmaceuticals

Cambridge, Massachusetts, US • 2460 Employees
SaaS

ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Rna Therapeutics Innovative Treatments Ocular Disease Treatment
Details about Alnylam Pharmaceuticals
Frequently Asked Questions about Yutaka Okada
Yutaka Okada currently works for Alnylam Pharmaceuticals.
Yutaka Okada's role at Alnylam Pharmaceuticals is President and Representative Director, Alnylam Japan KK.
Yutaka Okada's email address is ***@alnylam.com. To view Yutaka Okada's full email address, please signup to ConnectPlex.
Yutaka Okada works in the SaaS industry.
Yutaka Okada's colleagues at Alnylam Pharmaceuticals are Paula Cavallieri, Ilia Pharmd, Guodong Hui, Susan Galea, Holly Lindgren, Nami Tashiro, Jose Nolasco and others.
Yutaka Okada's phone number is (617) 551-8200
See more information about Yutaka Okada